Background {#Sec1}
==========

Diabetic kidney disease (DKD), an important complication of diabetes mellitus, is the leading cause of kidney failure in the western word and it is also associated with increased cardiovascular morbidity and mortality. Albuminuria and reduced glomerular filtration rate (GFR) are the key features of DKD. Traditionally, the earliest clinical manifestation of DKD has been the detection of persistent microalbuminuria \[[@CR1]\]. Early studies suggested that GFR starts to decrease only when albuminuria reaches the macroalbuminuric range \[[@CR2]\]. This conventional paradigm of kidney disease in people with diabetes has been recently challenged. Changes in albuminuria and GFR are being increasingly recognized as complementary rather than obligatory manifestations of DKD. Furthermore, albuminuria and loss of GFR seem to be associated with distinct clusters of specific risk factors. Several studies investigating the prevalence of both normoalbuminuric and albuminuric chronic kidney disease (CKD) have been performed in type 2 diabetes mellitus (T2DM) \[[@CR3]--[@CR7]\]. Limited information is available concerning heterogeneity of renal features in patients with type 1 diabetes mellitus (T1DM) and this is largely resulting from studies conducted in a few cohorts of patients with GFR ≤ 60 mL/min/1.73 m^2^ \[[@CR8]--[@CR10]\]. Recently, Penno et al. \[[@CR10]\] have recently assessed the prevalence and correlates of different CKD phenotypes in a cohort of 777 patients with T1DM (of which 29 with eGFR \< 60 mL/min/1.73 m^2^). They found that normoalbuminuric CKD phenotype is present in a significant proportion of the T1DM, a finding supporting two distinct pathways, with and without albuminuria, to advanced kidney disease.

We therefore analyzed a large sample of patients with T1DM and GFR ≤ 60 mL/min/1.73 m^2^ (with or without albuminuria) attending diabetes clinics and representative of current clinical practice for diabetes care in Italy to describe the differences in the clinical features associated with the two different CKD phenotypes (i.e. with and without albuminuria) and to investigate, in a subset of patients, the modulating role of albuminuria on kidney disease progression.

Methods {#Sec2}
=======

In this report, we show the results of an analysis performed using the data set of the electronic medical records collected on a large sample of patients with a diagnosis of T1DM (according to American Diabetes Association 2003 criteria), who attended 295 diabetes clinics in Italy between 1 January 2004, and 31 December 2011. Approximately, one-third of all the Italian diabetes clinics were involved in this study, evenly distributed throughout the country and therefore indicative of the clinical practice. For the purpose of the analysis, we considered only patients who were aged 18 years or older, with at least 1 outpatient measurement of serum creatinine and albuminuria and with a GFR ≤ 60 mL/min/1.73 m^2^. A total of 1395 patients (654 males and 741 females) constituted the study population (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).

The database derives from the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi---AMD) initiative designed to monitor diabetes care and quality of care as previously reported \[[@CR11]--[@CR13]\]. All participating clinics used an electronic clinical record system, and a software specifically developed to extract information. Data from all participating clinics were collected anonymously and were centrally analyzed \[[@CR11]--[@CR13]\]. The results were internally approved by the AMD Annals scientific committee. The core data-set included measures and monitoring of glycated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein cholesterol (LDL-c) or high density lipoprotein cholesterol (HDL-c), and triglycerides. The use of specific classes of drugs was also evaluated. Kidney function was assessed by serum creatinine, measured by modified Jaffè method, and urinary albumin excretion measurements (UAE). Glomerular filtration rate (GFR) was estimated for each patient by using the CKD epidemiology collaboration formula derived by serum creatinine values \[[@CR14]\]. Increased UAE was diagnosed as (1) microalbuminuria if urinary albumin concentration was \> 30 and ≤ 300 mg/L, or if UAE rate was \> 20 and ≤ 200 μg/min, or if urinary albumin-to-creatinine ratio was \> 2.5 mg/mmol in men and \> 3.5 mg/mmol in women and ≤ 30 mg/mmol in both gender and (2) macroalbuminuria if urinary albumin concentration was \> 300 mg/L, or if UAE rate was \> 200 μg/min, or if albumin-to-creatinine ratio was \> 30 mg/mmol in both gender. Urine albumin excretion was evaluated by means of urine albumin concentration in the majority of study patients 1020 (i.e. 73%) and by albumin to creatinine ratio (spot morning samples) in a smaller number of patients 344 (25%). Timed urine collection (24 h) was used in a minority of patients 31 (2%).

Albuminuria indicates patients with either microalbuminuria or macroalbuminuria. DKD was defined as diabetes with albuminuria and/or low GFR (≤ 60 mL/min/1.73 m^2^). Information on the presence of diabetic retinopathy, background (BR), or proliferative (PR), was also available. At each participating center, all patients underwent physical examination and blood pressure (BP) measurements according to a standardized protocol. BP was measured with the patient in the sitting position after a 5-min rest, with a mercury sphygmomanometer.

For the cross-sectional analyses, we extracted data from the most recent patients' visit complete of eGFR measurement and albuminuria evaluation. To obtain the 4-year evaluations, we selected for each patient the last 4-year period that included eGFR and albuminuria status at baseline and a re-evaluation of eGFR 4 years later. As a consequence of selection criteria, the baseline included a visit up to the year 2008 and the follow-up up to 2011 (range of visits 48 ± 6 months selecting that closest to 48 month). For patients without a re-evaluation at 4-year, the last visit up to the year 2008 was considered for the cross-sectional study (the same period of baseline visit for the longitudinal population).

Statistical analysis {#Sec3}
====================

Data are given as mean value ± standard deviation or median (interquartile range), and categorical variables are described as frequencies and percentages. Logistic regression analysis was used to evaluate variables associated to albuminuria. Predictors of eGFR reduction \> 30% \[[@CR15]\] than baseline were evaluated with a logistic model adjusting for baseline eGFR. A multivariate model was built selecting variables associated to the outcome with a P value \< 0.05 adjusting for age and gender. Multivariate analysis was performed as complete-case analysis including patients with all data available. The odds ratios (ORs) were used to estimate the degree of association with outcome. Assuming linearity of eGFR reduction over time, its slope was taken as a measure of disease progression rate. For each patients, we calculated the regression coefficient (slope) of linear regression between eGFR value and the exact time in years from the first evaluation including all measurements from baseline to the 4-year visit. The analyses were made using STATA software, Version 14 (StataCorp, College Station, TX). P values of \< 0.05 were considered statistically significant.

Results {#Sec4}
=======

The main clinical features of the study population (n = 1395) at baseline, as a whole and grouped by the presence/absence of albuminuria, are summarized in Table [1](#Tab1){ref-type="table"}. Overall, the mean age of patients was 63 ± 14 years, 46.9% were male and mean duration of diabetes was 27 ± 14 years. Taking into account the presence of CKD, glycemic and blood pressure controls were fairly good. A total of 986 (70.7%) and 611 (43.8%) patients were on antihypertensive and on lipid-lowering treatment, respectively. In our sample, albuminuria was detected in 676 (48.5%) patients, with the remaining 719 (51.5%) patients having normoalbuminuric renal impairment (Table [1](#Tab1){ref-type="table"}). Those with albuminuria were more likely to be males and, on average, younger respect to patients without albuminuria. Duration of disease was comparable between patients with or without albuminuria. Albuminuria was also associated with a worse glycemic control and higher levels of serum uric acid. Furthermore, albuminuria was associated with a more atherogenic lipid profile (i.e. higher LDL cholesterol and triglycerides levels and lower HDL-c) and higher values of systolic BP (SBP) and diastolic BP (DBP) despite a greater prevalence of antidyslipidemic and antihypertensive treatment.Table 1Baseline clinical characteristics of 1395 T1DM patients with low eGFR as whole and after stratification by the presence of albuminuriaOverallNormoalbuminuriaAlbuminuriaPn = 1395n = 719n = 676Male sex654 (46.9%)252 (35.0%)402 (59.5%)\< 0.001Age (years)63 ± 1466 ± 1260 ± 14\< 0.001Duration of diabetes (years)27 ± 1427 ± 1527 ± 130.968BMI (kg/m^2^)26.3 ± 4.726.2 ± 4.526.5 ± 4.90.201Serum creatinine (mg/dL)1.55 ± 0.811.35 ± 0.521.78 ± 0.98\< 0.001eGFR (mL/min/1.73 m^2^)46 ± 1249 ± 1043 ± 13\< 0.001Albuminuria676 (48.5%)----Serum uric acid (mg/dL)5.7 ± 1.85.3 ± 1.86.1 ± 1.6\< 0.001Serum uric acid in the top quintile162 (19.0%)60 (14.3%)102 (23.5%)0.001HbA1c (%)8.2 ± 1.68.0 ± 1.58.3 ± 1.7\< 0.001HbA1c (mmol/mol)66 ± 17.564.0 ± 16.467 ± 18.6\< 0.001HbA1c ≥ 7%1071 (77.4%)541 (75.7%)530 (79.2%)0.114HbA1c ≥ 54 mmol/mol1071 (77.4%)541 (75.7%)530 (79.2%)0.114Total cholesterol (mg/dL)195 ± 44192 ± 38198 ± 480.012Triglycerides (mg/dL)122 ± 82110 ± 74136 ± 89\< 0.001Triglycerides  ≥ 150 mg/dL292 (22.4%)113 (16.8%)179 (28.5%)\< 0.001HDL (mg/dL)60 ± 1961 ± 1958 ± 200.008HDL \< 40 M \< 50 F mg/dL269 (20.8%)133 (20.0%)136 (21.6%)0.491LDL (mg/dL)112 ± 35109 ± 32114 ± 380.027LDL ≥ 100 mg/dL785 (61.1%)402 (60.4%)383 (61.9%)0.578Systolic BP (mmHg)139 ± 20137 ± 20141 ± 20\< 0.001Diastolic BP (mmHg)77 ± 1076 ± 1078 ± 100.006Blood pressure ≥ 140/85 mmHg659 (57.8%)315 (53.9%)344 (61.9%)0.007Non-proliferative retinopathy279 (20.0%)152 (21.1%)127 (18.8%)0.272Proliferative retinopathy146 (10.5%)56 (7.8%)90 (13.3%)0.001Smokers107 (18.7%)40 (13.5%)67 (24.3%)0.001Lipid-lowering treatment611 (43.8%)301 (41.9%)310 (45.9%)0.133Treatment with statins579 (41.5%)287 (39.9%)292 (43.2%)0.214Treatment with fibrates14 (1.0%)9 (1.3%)5 (0.7%)0.343Antihypertensive treatment986 (70.7%)453 (63.0%)533 (78.8%)\< 0.001Treatment with ACE-Is/ARBs862 (61.8%)384 (53.4%)478 (70.7%)\< 0.001Aspirin339 (24.3%)158 (22.0%)181 (26.8%)0.037Insulin pump52 (3.7%)17 (2.4%)35 (5.2%)0.007Mean ± SD or absolute frequency (percentage). Patients' baseline missing data: duration of diabetes 72 (5.2%), BMI 212 (15.2%), serum uric acid 542 (38.9%), HbA1c 11 (0.8%), total cholesterol 73 (5.2%), triglycerides 92 (6.6%), HDL 99 (7.1%), LDL 110 (7.9%), blood pressure 255 (18.3%), smokers 823 (59.0%). Serum uric acid in the top gender-specific quintile: \> 6.6 mg/dL in females and \> 7.4 mg/dL in males*eGFR* estimated glomerular filtration rate, *BMI* body mass index, *HbA1c* glycated haemoglobin, *HDL* high-density lipoprotein cholesterol, *LDL* low-density lipoprotein cholesterol, *ACE-Is* angiotensin converting enzyme-inhibitors, *ARBs* angiotensin II receptor antagonists

As expected, individuals with albuminuria were more frequently treated with angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin II receptor antagonists (ARBs) as compared to those without albuminuria. Moreover, they were more likely to be smokers and to show proliferative retinopathy.

We have also compared clinical features of patients with micro or macroalbuminuria. Those with macroalbuminuria showed an evident worse cardiovascular (CV) risk profile as compared to patients with microalbuminuria (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

To investigate the differences in the kidney dysfunction progression between patients with low eGFR and normoalbuminuria or albuminuria, a subgroup of 582 patients, whose clinical features are showed in Table [2](#Tab2){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}: Table S2, was followed up over a 4-year period. One hundred and twenty five patients (21.5%) showed a loss of eGFR \> 30%. The proportion of patients reaching the renal outcome was significantly higher among those with baseline albuminuria as compared to patients with normoalbuminuria (33.6% vs 10.5%, albuminuria vs normoalbuminuria, respectively P \< 0.0001). The slope of GFR decline was of − 0.5 (− 2.2; 1.5) mL/min/1.73 m^2^/year for the whole sample. Patients with normoalbuminuria showed a stable kidney function along the follow-up period \[i.e. + 0.4 (− 1.2; 3.2) mL/min/1.73 m^2^/year\] while those with albuminuria had a significant progression of kidney disease \[− 1.3 (− 3.2; 0.3) mL/min/1.73 m^2^/year\]. The main baseline clinical features of the above study population grouped by renal outcome at 4-year follow-up are summarized in Table [3](#Tab3){ref-type="table"}. Patients who went on to develop renal outcome showed a poor glycemic control and higher levels of triglycerides and serum uric acid as compared to patients who did not. Furthermore, they had higher levels of SBP despite a greater prevalence of antihypertensive treatment.Table 2Baseline clinical characteristics of 582 type 1 diabetes mellitus patients with low eGFR and with 4 year follow-up, overall and on the basis of albuminuriaOverallNormoalbuminuriaAlbuminuriaPn = 582n = 305n = 277Male sex262 (45.0%)99 (32.5%)163 (58.8%)\< 0.001Age (years)63 ± 1365 ± 1260 ± 13\< 0.001Duration of diabetes (years)27 ± 1326 ± 1427 ± 120.385BMI (kg/m^2^)27 ± 526 ± 427 ± 60.085Serum creatinine (mg/dL)1.55 ± 0.901.31 ± 0.401.81 ± 1.19\< 0.001eGFR (mL/min/1.73 m^2^)47 ± 1250 ± 1043 ± 13\< 0.001eGFR (mL/min/1.73 m^2^)50 (39--56)52 (45--57)46 (35--54)\< 0.001Serum uric acid (mg/dL)5.6 ± 1.65.1 ± 1.46.1 ± 1.6\< 0.001Serum uric acid in the top quintile65 (18.2%)20 (11.4%)45 (24.7%)0.001HbA1c (%)8.1 ± 1.58.0 ± 1.38.3 ± 1.60.036HbA1c (mmol/mol)65 ± 16.464 ± 14.267 ± 17.50.036HbA1c ≥ 7%453 (78.5%)234 (77.2%)219 (79.9%)0.431HbA1c ≥ 54 mmol/mol453 (78.5%)234 (77.2%)219 (79.9%)0.431Total cholesterol (mg/dL)196 ± 40197 ± 37195 ± 430.677Triglycerides (mg/dL)121 ± 81110 ± 82133 ± 790.002Triglycerides ≥ 150 mg/dL118 (22.1%)46 (16.6%)72 (28.0%)0.002HDL (mg/dL)59 ± 1962 ± 1957 ± 180.004HDL \< 40 M \< 50 F mg/dL105 (19.7%)54 (19.5%)51 (20.0%)0.884LDL (mg/dL)113 ± 33113 ± 31112 ± 350.636LDL ≥ 100 mg/dL349 (66.0%)188 (68.1%)161 (63.6%)0.278Systolic BP (mmHg)139 ± 19137 ± 19141 ± 190.032Diastolic BP (mmHg)77 ± 977 ± 978 ± 100.204Blood pressure  ≥ 140/85 mmHg276 (59.2%)138 (56.1%)138 (62.7%)0.146Non-proliferative retinopathy123 (21.1%)64 (21.0%)59 (21.3%)0.926Proliferative retinopathy68 (11.7%)24 (7.9%)44 (15.9%)0.003Smokers46 (18.8%)20 (14.5%)26 (24.3%)0.053Lipid-lowering treatment253 (43.5%)124 (40.7%)129 (46.6%)0.151Treatment with statins238 (40.9%)115 (37.7%)123 (44.4%)0.101Treatment with fibrates8 (1.4%)5 (1.6%)3 (1.1%)0.568Antihypertensive treatment421 (72.3%)199 (65.2%)222 (80.1%)\< 0.001Treatment with ACE-Is/ARBs372 (63.9%)171 (56.1%)201 (72.6%)\< 0.001Aspirin139 (23.9%)67 (22.0%)72 (26.0%)0.256Insulin pump18 (3.1%)2 (0.7%)16 (5.8%)0.0034-year eGFR reduction \> 30%125 (21.5%)32 (10.5%)93 (33.6%)\< 0.001eGFR at follow-up (mL/min/1.73 m^2^)47 (33--58)53 (41--66)38 (25--49)\< 0.001Mean ± SD, median (interquartile range) or absolute frequency (percentage). Patients' baseline missing data: duration of diabetes 18 (3.1%), BMI 108 (18.6%), serum uric acid 225 (38.7%), HbA1c 5 (0.9%), total cholesterol 41 (7.0%), triglycerides 48 (8.2%), HDL 50 (8.6%), LDL 53 (9.1%), blood pressure 116 (19.9%), smokers 337 (57.9%)*eGFR* estimated glomerular filtration rate, *BMI* body mass index, *HbA1c* glycated haemoglobin, *HDL* high-density lipoprotein cholesterol, *LDL* low-density lipoprotein cholesterol, *ACE-Is* angiotensin converting enzyme-inhibitors, *ARBs* angiotensin II receptor antagonists Table 3Baseline clinical characteristics of 582 type 1 diabetes mellitus patients reaching the renal end-point (estimated Glomerular filtration rate reduction \> 30%)4-year eGFR reduction \> 30%PNoYesn = 457n = 125Male sex197 (43.1%)65 (52.0%)0.149Age (years)63 ± 1361 ± 140.295Known duration of diabetes (years)27 ± 1327 ± 130.726BMI (kg/m^2^)26 ± 527 ± 60.277Serum creatinine (mg/dL)1.49 ± 0.861.75 ± 1.020.501eGFR (mL/min/1.73 m^2^)48 ± 1143 ± 13\< 0.001Albuminuria184 (40.3%)93 (74.4%)\< 0.001Microalbuminuria131 (28.7%)41 (32.8%)0.001Macroalbuminuria53 (11.6%)52 (41.6%)\< 0.001Serum uric acid (mg/dL)5.4 ± 1.56.2 ± 1.80.004Serum uric acid in the top gender-specific quintile40 (14.5%)25 (30.9%)0.038HbA1c (%)8.1 ± 1.48.4 ± 1.50.049HbA1c (mmol/mol)65 ± 15.368 ± 16.40.049HbA1c ≥ 7%350 (77.3%)103 (83.1%)0.129HbA1c ≥ 53 mmol/mol350 (77.3%)103 (83.1%)0.129Total cholesterol (mg/dL)196 ± 38196 ± 480.912Triglycerides (mg/dL)114 ± 63147 ± 1250.003Triglycerides ≥ 150 mg/dL84 (19.9%)34 (30.4%)0.054HDL (mg/dL)60 ± 1956 ± 180.086HDL \< 40 M \< 50 F mg/dL81 (19.2%)24 (21.8%)0.791LDL (mg/dL)113 ± 30112 ± 420.964LDL ≥ 100 mg/dL280 (66.8%)69 (62.7%)0.585Systolic BP (mmHg)138 ± 19143 ± 200.040Diastolic BP (mmHg)77 ± 978 ± 100.128BP ≥ 140/85 mmHg208 (57.3%)68 (66.0%)0.092Non-proliferative retinopathy99 (21.7%)24 (19.2%)0.850Proliferative retinopathy44 (9.6%)24 (19.2%)0.008Smokers32 (16.8%)14 (25.9%)0.060Lipid-lowering treatment193 (42.2%)60 (48.0%)0.302Treatment with statins184 (40.3%)54 (43.2%)0.589Treatment with fibrates5 (1.1%)3 (2.4%)0.308Antihypertensive treatment317 (69.4%)104 (83.2%)0.010Treatment with ACE-Is/ARBs284 (62.1%)88 (70.4%)0.226Aspirin107 (23.4%)32 (25.6%)0.715Insulin pump10 (2.2%)8 (6.4%)0.050Mean ± SD or absolute frequency (percentage). Patients' baseline missing data: duration of diabetes 18 (3.1%), BMI 108 (18.6%), serum uric acid 225 (38.7%), HbA1c 5 (0.9%), total cholesterol 41 (7.0%), triglycerides 48 (8.2%), HDL 50 (8.6%), LDL 53 (9.1%), blood pressure 116 (19.9%), smokers 337 (57.9%)*eGFR* estimated glomerular filtration rate, *BMI* body mass index, *HbA1c* glycated haemoglobin, *HDL* high-density lipoprotein cholesterol, *LDL* low-density lipoprotein cholesterol, *ACE-Is* angiotensin converting enzyme-inhibitors, *ARBs* angiotensin II receptor antagonistsThe P value refers to the effect of each variable on 4-year eGFR reduction \> 30% at logistic regression analysis adjusted for baseline eGFR

As expected, they had also a lower eGFR at baseline (43 vs. 48 mL/ min/1.73 m^2^, P \< 0.001).

Almost 2/3 of patients who went on to develop eGFR reduction \> 30% showed albuminuria at baseline and 19% showed proliferative retinopathy. At the multivariate logistic analysis microalbuminuria, macroalbuminuria and proliferative retinopathy were the only parameters independently associated to eGFR reduction (Table [4](#Tab4){ref-type="table"}).Table 4Baseline predictors at multivariate analysis for 4-year eGFR reduction \> 30%Odds ratioPOdds ratioPMale sex0.95 (0.55--1.65)0.8610.87 (0.49--1.53)0.620Age (by 10 years)0.90 (0.73--1.11)0.3310.95 (0.76--1.18)0.615eGFR (by 10 mL/min/1.73 m^2^)0.86 (0.70--1.06)0.1640.89 (0.72--1.11)0.303Albuminuria4.09 (2.22--7.56)\< 0.001--Microalbuminuria--2.50 (1.26--4.95)0.009Macroalbuminuria--9.25 (4.44--19.25)\< 0.001HbA1c (by 1%)1.10 (0.92--1.31)0.2991.06 (0.88--1.27)0.559Triglycerides (by 10 mg/dL)1.02 (0.99--1.05)0.2371.02 (0.99--1.06)0.248Systolic blood pressure (by 10 mmHg)1.11 (0.97--1.27)0.1451.09 (0.95--1.25)0.232Proliferative retinopathy2.39 (1.22--4.68)0.0112.36 (1.18--4.73)0.016Antihypertensive treatment2.19 (0.97--4.92)0.0592.14 (0.93--4.92)0.074Complete case analysis performed by using a logistic regression model including 427 patients (91 with eGFR reduction \> 30%) for which all data were observed*eGFR* estimated glomerular filtration rate, *HbA1c* glycated haemoglobin

Discussion {#Sec5}
==========

In a large cohort representative of real life clinical practice in Italy, we found that up to 50% of patients with T1DM and CKD show a non albuminuric phenotype. In addition, we demonstrate that the loss of GFR is much greater in T1DM albuminuric CKD as compared with T1DM normoalbuminuric CKD patients.

The prevalence of normoalbuminuric CKD in our population was higher than that in the Finnish Diabetic Nephropathy Study \[[@CR16]\] where, of the 502 patients with CKD, 78 (16%) did not have albuminuria. This difference could likely be accounted for by differences in patients' clinical features and in setting were the patients have been studied. A cross-sectional survey of the UK National Diabetes Audit \[[@CR9]\] investigating a large cohort of T1DM patients has recently reported the presence of normoalbuminuria in 54.4% of individuals stage ≥ 3 CKD, a proportion similar to our finding. In a very recent retrospective study by Penno et al. \[[@CR10]\], the authors found that, among 29 patients with eGFR \< 60 mL/min/1.73 m^2^, 17 (58.6%) had normoalbuminuria. The authors couldn't find any significant differences for most of clinical variables investigated, very likely because of the small number of patients evaluated. Furthermore, the study conducted by Penno et al. was a cross-sectional, single-centre study while in our study the patients were recruited from more than 200 diabetes clinics in Italy distributed throughout the country and therefore indicative of the clinical practice in the real life condition. The pathophysiology and clinical significance of low GFR levels in patients without albuminuria is to this day unclear. While in patients with T2DM the occurrence of non albuminuric renal impairment has been related to pathogenetic mechanisms such as premature kidney senescence, interstitial fibrosis, ischaemic vascular disease or cholesterol microemboli \[[@CR3]\] which may differ from those involved in the development of traditional diabetic glomerulosclerosis, it is currently uncertain whether a similar pathogenetic scenario also applies to T1DM patients with non albuminuric renal dysfunction. Glomerular structural changes typical of diabetic nephropathy, have been reported in T1DM patients with normoalbuminuria and reduced GFR \[[@CR17]\]. In these patients, a thickening of the glomerular basal membrane and a greater fractional volume of the glomerulus occupied by mesangium have been found as compared with those who had a normal GFR. Probably the expression of some proteins, such as nephrin, responsible of the integrity of the slit diaphragm, remains unchanged in patients with normoalbuminuric renal insufficiency \[[@CR18]\].

When we focused on differences in the kidney dysfunction progression we found that the loss of GFR was greater in albuminuric CKD patients as compared to normoalbuminuric CKD patients. Patients with normoalbuminuria showed a stable kidney function along the follow-up period while those with albuminuria had a significant progression of kidney disease. This finding is in line with the results of Holfiel et al. who described the accelerating effect of albuminuria in the loss of GFR in patients with T1DM and T2DM \[[@CR19]\]. Normoalbuminuric renal impairment is a widely described strong risk factor for cardiovascular mortality and morbidity in the general population and in patients with T2DM \[[@CR20]\]. Data on this specific issue in patients with T1DM are lacking.

Our study has several limitations as well as strengths. First of all, laboratory variables were not centralized and this could have caused variability especially in the creatinine assay. However, most laboratories around the country currently use the modified Jaffè method, which has good reproducibility. In addition, we have classified our patients using only one measurement of albuminuria. This is in line with other studies \[[@CR21], [@CR22]\]. Pugliese et al. \[[@CR21]\] have recently reported in a large cohort of subjects with T2DM participating in the renal insufficiency and cardiovascular events (RIACE) Italian Multicentre Study, that a single UAE value, thought to be encumbered with high intra-individual variability, is an accurate predictor of nephropathy stage for clinical and epidemiological purposes. On the other hand, the large number of patients studied and the consistent geographical distribution of the recruiting centers are major strengths of the study, which gives missing information about this issue in Italy. Further limitations merit to be mentioned, i.e. lack of information on: (i) previous cardiovascular events, cancer, infection and hospitalization during the follow-up period, (ii) historical albuminuria data and (iii) duration of smoking habit.

In conclusion, our study shows as the proportion of T1DM patients with normoalbuminuria renal impairment is high (about 50%). These patients have a slower eGFR decline as compared to that observed in patients with albuminuria renal impairment. Whether T1DM patients with albuminuric renal impairment as compared to patients with normoalbuminuric renal impairment need a more intensive renal protection treatment will be clarified by further intervention studies.
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DKD

:   diabetic kidney disease

GFR

:   glomerular filtration rate

T2DM

:   type 2 diabetes mellitus

T1DM

:   type 1 diabetes mellitus

CKD

:   chronic kidney disease

HbA1c

:   glycated hemoglobin

LDL-c

:   low-density lipoprotein cholesterol

HDL-c

:   high density lipoprotein cholesterol

UAE

:   urinary albumin excretion measurements

BR

:   background retinopathy

PR

:   proliferative retinopathy

BP

:   blood pressure

ORs

:   odds ratios

ACE-Is

:   angiotensin converting enzyme inhibitors

ARBs

:   angiotensin II receptor antagonists

CV

:   cardiovascular

IDMS

:   isotope dilution mass spectrometry

OL, FV, RP, SDC designed research; OL, RP, SDC performed research; OL, PG, RP, SDC analyzed data; OL, RP, SDC wrote the paper; OL, FV. PF, AM, CG, AC, GR, PG, RP, SDC reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

We thank the AMD-Annals Study Group.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

All data generated or analysed during this study are included in this published article and its additional files.

Consent for publication {#FPar4}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar5}
==========================================

The study was approved by AMD Annals scientific committee.

Funding {#FPar6}
=======

Not applicable.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
